Is Shendafinelidone the world's first product?

Finerenone (Finerenone) is a nonsteroidal antiandrogen receptor (anti-MR) drug used to treat heart failure and diabetic nephropathy. It was first developed by Bayer and was approved for marketing by the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA) in 2020. Therefore, Cosendafinelidone is not the world's first drug. Over the past few decades, extensive research into heart failure and diabetic nephropathy has been conducted globally, and many drugs have been developed to treat these diseases. Fenelidone is one of a number of drugs that have been used to treat these conditions.

The research and development process of fenelidone is a long and complex process. Scientists have conducted in-depth research on the pathogenesis of heart failure and diabetic nephropathy and found that androgen receptor (MR) plays an important role in the development of these two diseases. In this research process, Bayer played an important role. They have made important breakthroughs in the process of exploring the development of new drugs, especially drugs targeting MR. It was against this background that fenelidone was discovered and developed. Researchers confirmed its efficacy in heart failure and diabetic nephropathy through clinical trials of the drug, and ultimately obtained approval for marketing.

The pivotal escape trial that served as the basis for the FDA approval demonstrated the extraordinary potential of fenelidone, which showed that compared with placebo, it resulted in a significant 18% reduction in the risk of death and a 23% significant reduction in the risk of hospitalization for heart failure. These findings highlight the critical role of fenelidone in improving survival and reducing hospitalization burden, thereby providing a much-needed treatment option for T2D and CKD patients with HFrEF.